Network-pharmacology-based research on protective effects and underlying mechanism of Shuxin decoction against myocardial ischemia/reperfusion injury with diabetes

Figure 9 Echocardiography and cardiac damage markers. A: Echocardiography after 2 h reperfusion; B: Left ventricular ejection fraction after 2 h reperfusion; C: Left ventricular fractional shortening after 2 h reperfusion; D: Creatine kinase isoenzyme MB at the end of the experiment; E: Troponin T at the end of the experiment; F: Lactate dehydrogenase at the end of the experiment. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs group C. ^dP < 0.05, ^eP < 0.01, ^fP < 0.001 vs myocardial ischemia/reperfusion injury in diabetes group (n = 3 rats per group). C: Normal control group; DS: Diabetic rats with sham operation group; MI/RI: Myocardial ischemia/reperfusion injury; DMR: MI/RI in diabetes group; SXTL: MI/RI in diabetic rats receiving SXT 0.7 g/kg/d group; SXTM: MI/RI in diabetic rats receiving SXT 1.4 g/kg/d group; SXTH: MI/RI in diabetic rats receiving SXT 2.8 g/kg/d group; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening; CKMB: Creatine kinase isoenzyme MB; cTnT: Troponin T; LDH: Lactate dehydrogenase.